Thyrocare Technologies (NSE:THYROCARE) Cyclically Adjusted Revenue per Share: ₹40.19 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
89 GF Score
Price ₹642.95
GF Value ₹423.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Cyclically Adjusted Revenue per Share?

Thyrocare Technologies NSE:THYROCARE -0.99% 89 Cyclically Adjusted Revenue per Share is ₹40.19 as of Jun. 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹423.45 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Thyrocare Technologies's adjusted revenue per share for the three months ended in Jun. 2026 was ₹14.809. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹40.19 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Thyrocare Technologies's average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-13), Thyrocare Technologies's current stock price is ₹642.95. Thyrocare Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹40.19. Thyrocare Technologies's Cyclically Adjusted PS Ratio of today is 16.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thyrocare Technologies was 15.01. The lowest was 6.01. And the median was 9.29.


Thyrocare Technologies  (NSE:THYROCARE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Thyrocare Technologies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=642.95/40.19
=16.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thyrocare Technologies was 15.01. The lowest was 6.01. And the median was 9.29.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Thyrocare Technologies Cyclically Adjusted Revenue per Share Related Terms


Thyrocare Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Cyclically Adjusted Revenue per Share Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 32.93 34.79 38.94

Thyrocare Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.86 37.12 38.01 38.94 40.19

NSE:THYROCARE vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Thyrocare Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thyrocare Technologies Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Thyrocare Technologies's Cyclically Adjusted PS Ratio falls into.


NSE:THYROCARE
89GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Thyrocare Technologies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.809/166.1454*166.1454
=14.809

Current CPI (Jun. 2026) = 166.1454.

Thyrocare Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.894 105.961 7.674
201612 4.367 105.196 6.897
201703 5.467 105.196 8.635
201706 5.436 107.109 8.432
201709 5.450 109.021 8.306
201712 5.235 109.404 7.950
201803 5.974 109.786 9.041
201806 6.020 111.317 8.985
201809 6.429 115.142 9.277
201812 6.053 115.142 8.734
201903 6.391 118.202 8.983
201906 6.911 120.880 9.499
201909 7.418 123.175 10.006
201912 6.658 126.235 8.763
202003 6.056 124.705 8.068
202006 3.262 127.000 4.267
202009 9.647 130.118 12.318
202012 8.709 130.889 11.055
202103 8.890 131.771 11.209
202106 10.349 134.084 12.824
202109 11.085 135.847 13.557
202112 7.372 138.161 8.865
202203 7.774 138.822 9.304
202206 8.037 142.347 9.381
202209 8.485 144.661 9.745
202212 8.031 145.763 9.154
202303 7.971 146.865 9.017
202306 8.495 150.280 9.392
202309 9.314 151.492 10.215
202312 8.105 152.924 8.806
202403 9.826 153.035 10.668
202406 9.877 155.789 10.534
202409 11.039 157.882 11.617
202412 9.898 158.323 10.387
202503 11.902 157.552 12.551
202506 11.900 159.755 12.376
202509 13.581 162.289 13.904
202512 12.200 163.281 12.414
202603 14.163 164.272 14.324
202606 14.809 166.145 14.809

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹40.19 mean?
Thyrocare Technologies (NSE:THYROCARE) has a Cyclically Adjusted Revenue per Share of ₹40.19 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thyrocare Technologies and its competitors.
Is Thyrocare Technologies' Cyclically Adjusted Revenue per Share too high?
Thyrocare Technologies' current Cyclically Adjusted Revenue per Share is ₹40.19. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Thyrocare Technologies' Cyclically Adjusted Revenue per Share of ₹40.19 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Cyclically Adjusted Revenue per Share is ₹40.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹423.45, compared to a current price of ₹642.95 — trading 51.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹40.19. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Cyclically Adjusted Revenue per Share is ₹40.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹642.95 is trading 51.8% above its estimated GF Value™ of ₹423.45. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • Cyclically Adjusted Revenue per Share: ₹40.19
  • GF Value™: ₹423.45 vs. price of ₹642.95 (51.8% above fair value)
  • GF Score™: 89/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score

Get the complete analysis for NSE:THYROCARE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹642.95
Price
₹423.45
GF Value